To lyse or not to lyse: Is it genetic?

Italian Heart Journal

Volumn 2, Issue 9, 2001, Pages 652-655

  Carter, A M ^a   Grant, P J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cardiovascular disease; Fibrinolysis; Genetic markers; Polymorphism

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FIBRINOLYSIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; HEREDITY; HUMAN; PATHOGENESIS;

BLOOD CIRCULATION; CARDIOVASCULAR DISEASES; FIBRINOLYSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 0034755579     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
2. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up
3. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
4. Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease
5. Abnormally high circulating levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke
6. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor
7. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with non-diabetic patients. A potential factor predisposing to thrombosis and its persistence
8. PAI-1 concentrations in first degree relatives of patients with non-insulin-dependent diabetes mellitus: Metabolic and genetic associations
9. Plasminogen-activator inhibitor type 1 and coronary artery disease
10. Genetic determinants of hemostasis phenotypes in Spanish families
11. The genetics of haemostasis: A twin study
12. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event
13. Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA
14. Tissue plasminogen activator and the risk of myocardial infarction: The Rotterdam study
15. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
16. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
17. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography
18. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
19. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
20. Determinants of plasminogen activator inhibitor-1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene
21. Plasminogen activator inhibitor-1 promoter polymorphism and coronary artery disease in non-insulin dependent diabetes
22. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
23. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene
24. Inhibition of factor XIIIa in a canine model of coronary thrombosis: Effect of reperfusion and acute re-occlusion after recombinant tissue-type plasminogen activator
25. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolus
26. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model